News Release

Cold Spring Harbor Protocols Book Cites Cleanascite™ for Ascites Clarification

MONMOUTH JUNCTION, NJ, November 15, 2021 -- Biotech Support Group reports on a research article describing the simplicity and efficiency of their lipid depletion technology to clarify ascites fluid to recover monoclonal antibodies. The citation is:

Greenfield, Edward A. "Inducing, collecting, and storing ascites." Cold Spring Harbor Protocols 2021.10 (2021): pdb-prot103309.

Ascitic fluid (also called ascites) is an intraperitoneal fluid extracted from mice that have developed a peritoneal tumor. For antibody production, the tumor is induced by injecting hybridoma cells into the peritoneum, which serves as a growth chamber for the cells. The hybridoma cells grow to high densities and continue to secrete the antibody of interest, thus creating a high-titered solution of antibodies for collection. In the TROUBLESHOOTING section, the book states:

Problem (Step 8): A precipitate of lipids and/or cryoproteins has formed.

Solution: This may be produced by long-term storage at 4°C. These precipitates can be removed by centrifugation or by using Cleanascite (Biotech Support Group X2555) for clarification.

“Its very rewarding to see how Cleanascite™ can enhance cancer research associated with the selective removal of fatty acids. Cleanascite™ is an aqueous suspension product without harmful solvents, or any other non-specific cytotoxic effects. This ultimately helps researchers decide whether or not lipids, or factors interacting with lipids, impart characteristic changes in cells. This article exemplifies such utility.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group

Click to visit Cleanascite™ product page and ordering information

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for Covid-19 and cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com